GenScript Biotech Corporation, a leading provider of life-science research tools and services, announced the expansion of its Singapore facility to provide a premium gene synthesis service. The move adds an additional 976 square meters to the facility, bringing the total production footprint in Singapore to 3,500 square meters and making it the third-largest GenScript facility worldwide. The expansion will also increase the total headcount at the Singapore facility to 150.
In February 2022, GenScript Asia-Pacific announced the opening of a new recombinant protein production facility; now, that same facility will offer an advanced gene synthesis service. This marks an expansion of the company’s advanced gene-synthesis capability and enables GenScript to provide the premium service levels required for novel vaccine and therapeutics development in life sciences.
The Singapore facility houses state-of-the-art automated workstations capable of synthesizing more than 400 genes per day. This automated technique enables precise measurement, eliminates human errors, and ensures a consistently high-quality product. The new facility aims to reduce project turnaround time for an increasingly global mix of customers while ensuring customer data are secured in Singapore. The capacity of the new facility is committed to supporting cell and gene therapy research and vaccine development programs.